Influenza A Virus, H5N1 Subtype Clinical Trial
Official title:
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010)
This study will compare the different immune responses to Influenza A (H5N1) Virus Monovalent Vaccine with and without the AS03 adjuvant. The Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant vaccine is approved for use for adults to protect against flu caused by the A/H5N1 "bird flu" virus in Europe but none of the vaccines to be used in the study are approved for use in the United States. The results of this study will help researchers learn about better ways to vaccinate people against the H5N1 flu.
The influenza virus (a germ) causes influenza or "flu." The flu is an infection of the
breathing tubes and the lungs. In recent years, flu viruses that at first only infected birds
have begun to infect humans. One of these strains is called avian influenza (A/H5N1 subtype)
or "bird flu". Although no human cases of bird flu have been diagnosed in the United States,
this strain has caused severe illness and death in several hundred people since late 2003. .
Vaccination is the most effective way of controlling flu and preventing its illness and
complications. Vaccines help prevent illness by causing the body to make antibodies that
fight infection. One way to improve the effectiveness of a vaccine is to include a substance
that can stimulate the immune system to make more antibodies. This type of substance is
called an adjuvant; one type of adjuvant is called AS03 (Adjuvant System 03).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03497845 -
Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59
|
Phase 2 | |
| Completed |
NCT00489931 -
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
|
Phase 1 | |
| Completed |
NCT01086657 -
An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...
|
Phase 1 | |
| Completed |
NCT00408109 -
Safety Study of Avian Flu Vaccine
|
Phase 1 | |
| Completed |
NCT02107807 -
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
|
Phase 3 |